Newsroom

NIBIB-funded researchers have developed an interlinked tissue chip system that can model four mature organs in their perspective environments simultaneously. These multi-organ tissue chips could represent a new way to evaluate diseases or drugs that affect multiple different tissues.

The National Institutes of Health, through its Blueprint MedTech program, has established two incubator hubs and launched a funding solicitation in support of commercially viable, clinically focused neurotechnology solutions to diagnose and treat disorders of the nervous system.

One team helped develop the first photon-counting detector (PCD)-CT system, which is superior to current CT technology. Another team has also been using artificial intelligence to lower the dose of radiation given to a patient when they are undergoing a conventional CT brain scan.

A research team developed a microscope that combines rapid high- and low-power light-sheet microscopy with an open top design that allows for rapid imaging of a wide range of sample types

Minority patient groups may receive less supplemental oxygen in the ICU due to inaccurate readings from pulse oximeters.

Improvements in brain sensing technologies have allowed clinicians to perform increasingly complex surgeries and enabled researchers to map the signals of the brain that control feeling, movement, and thought.

Osteoarthritis – a painful condition that results from the deterioration of the cartilage in our joints – affects millions of people worldwide. To combat this issue, NIBIB-funded researchers are developing an implantable, biodegradable film that helps to regenerate the native cartilage at the site of damage. Their study, performed in rabbits, could be an initial, important step in the establishment of a new treatment.

NIBIB-funded researchers are developing an imaging method that would allow surgeons to better identify cancerous cells in breast tumor margins during surgery. This technique could lead to a reduction in follow-up breast cancer surgeries and reduce rates of breast cancer recurrence.

Photoacoustic (PA) imaging is a non-ionizing imaging platform that combines light and ultrasound to safely image structures and molecules in the body. Researchers have now designed a nanoparticle-based PA contrast agent that targeted and significantly enhanced photoacoustic images of ovarian tumors in a mouse model.